Onemednet Corporation has selected Inka Health, a subsidiary of Onco-Innovations Limited, to spearhead a groundbreaking AI-driven oncology project. The initiative aims to enhance the process of bringing cancer therapies to market by utilizing OneMedNet's regulatory-grade patient data to develop external control arms (ECAs). This innovative approach promises a more efficient and cost-effective alternative to traditional clinical trials, potentially accelerating access to life-saving treatments. By leveraging real-world data, the project seeks to expedite regulatory and reimbursement approvals, particularly in areas with high unmet needs such as colorectal cancer. This collaboration marks a significant step forward in the use of real-world evidence for cancer therapeutics, aligning with the growing trend of employing data-driven methodologies to optimize clinical development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.